Host intestinal mucosal interface

The host intestinal mucosal interface is a dynamic and multi-component system that serves as the primary boundary between the body's internal environment and the external contents of the gastrointestinal tract (PMID: 25113126). It is composed of a physical barrier (the mucus layer and a single layer of epithelial cells), a chemical barrier (antimicrobial peptides and secretory IgA), and a complex immunological network within the lamina propria (PMID: 23434588). This interface is essential for maintaining homeostasis by facilitating the absorption of nutrients and water while simultaneously preventing the translocation of commensal bacteria, pathogens, and dietary antigens (PMID: 28123927). Dysregulation of the intestinal mucosal interface, often referred to as "leaky gut," is implicated in the pathogenesis of numerous conditions, including inflammatory bowel disease (IBD), celiac disease, and certain systemic metabolic disorders (PMID: 23434588). Therapeutic interventions targeting this interface aim to restore barrier function, modulate local immune activity, or influence the composition of the gut microbiota to alleviate inflammation and promote mucosal healing (PMID: 30124827). Drugs like Teduglutide act on this interface by promoting epithelial growth, while biologics like Vedolizumab target the trafficking of immune cells to the mucosal site (PMID: 24869722). Overall, the integrity of this interface is a critical determinant of both local gastrointestinal health and systemic immune tolerance (PMID: 25113126).

Other names

Intestinal mucosal barrierGut-mucosal interfaceGastrointestinal barrierIntestinal epithelial barrier

Drugs targeting the host intestinal mucosal interface act through diverse mechanisms to maintain or restore barrier integrity and immune homeostasis. GLP-2 receptor agonists like Teduglutide promote the growth and maintenance of the intestinal epithelium, increasing villus height and crypt depth (PMID: 30124827). Integrin antagonists like Vedolizumab specifically block the alpha-4 beta-7 integrin on T-lymphocytes, preventing their migration from the blood into the inflamed intestinal mucosa (PMID: 24869722). Anti-TNF agents (e.g., Infliximab) and other cytokine inhibitors reduce the inflammatory burden that compromises barrier function (PMID: 10566716). Investigational agents like Larazotide acetate aim to regulate tight junction permeability by inhibiting the action of zonulin (PMID: 26000333). Additionally, secretagogues like Lubiprostone can influence the mucus layer and fluid dynamics to support mucosal defense (PMID: 19361154).